The noradrenergic action in antidepressant treatments: Pharmacological and clinical aspects

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 723-732

  Dell'Osso, Bernardo ^a   Palazzo, M Carlotta ^a   Oldani, Lucio ^a   Altamura, A Carlo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Major depression; Noradrenaline; Noradrenergic compounds

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; DESIPRAMINE; DESVENLAFAXINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; NORTRIPTYLINE; QUETIAPINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ANOREXIA; ANTICHOLINERGIC SYNDROME; ANXIETY; AROUSAL; BIPOLAR DISORDER; BLURRED VISION; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIZZINESS; DROWSINESS; DRUG MECHANISM; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HEART RATE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; JAUNDICE; LIVER TOXICITY; MAJOR DEPRESSION; MELANCHOLIA; MOTOR ACTIVITY; NAUSEA; NERVOUSNESS; NEUROANATOMY; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PHOTOSENSITIVITY; POSTTRAUMATIC STRESS DISORDER; RASH; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BEHAVIOR; DOPAMINE UPTAKE INHIBITORS; HUMANS; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; PSYCHOTROPIC DRUGS; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SYMPATHETIC NERVOUS SYSTEM; SYNAPTIC TRANSMISSION;

EID: 82355191865     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00217.x     Document Type: Review

References (115)

1. Bunney WE, Jr., Davis JM. Norepinephrine in depressive reactions. A review. Arch Gen Psychiatry 1965;13:483-494.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1995;122:509-522.
3. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: Novel concepts, new drugs. Neurotherapeutics 2009;6:53-77.
4. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 2010;16:1-17.
5. Mitchell ND, Baker GB. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 2010;122:192-210.
6. Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M, Daskalakis ZJ. Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 2010;67:458-464.
7. Müller N, Schwarz MJ. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert Rev Neurother 2006;6:1017-1038.
8. Loftis JM, Huckans M, Morasco BJ. Neuroimmune mechanisms of cytokine-induced depression: Current theories and novel treatment strategies. Neurobiol Dis 2010;37:519-533.
9. Wasserman D, Wasserman J, Sokolowski M. Genetics of HPA-axis, depression and suicidality. Eur Psychiatry 2010;25:278-280.
10. Janssen DG, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010;25:201-215.
11. Cattaneo A, Sesta A, Calabrese F, Nielsen G, Riva MA, Gennarelli M. The expression of VGF is reduced in leukocytes of depressed patients and it is restored by effective antidepressant treatment. Neuropsychopharmacology 2010;35:1423-1428.
12. Bocchio-Chiavetto L, Bagnardi V, Zanardini R, et al. Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. World J Biol Psychiatry 2010;11:763-773.
13. Katz MM, Bowden CL, Frazer A. Rethinking depression and the actions of antidepressants: Uncovering the links between the neural and behavioral elements. J Affect Disord 2010;120:16-23.
14. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;33:2609-2614.
15. Katz MM, Maas JW. Psychopharmacology and the etiology of psychopathologic states: Are we looking in the right way Neuropsychopharmacology 1994;10:139-144.
16. Handley SL. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 1995;66:103-148.
17. Morilak DA, Frazer A. Antidepressants and brain monoaminergic systems: A dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2004;7:193-218.
18. Racagni G, Brunello N. Physiology to functionality: The brain and neurotransmitter activity. Int Clin Psychopharmacol 1999;14(Suppl 1):S3-S7.
19. Geerling JC, Shin JW, Chimenti PC, Loewy AD. Paraventricular hypothalamic nucleus: Axonal projections to the brainstem. J Comp Neurol 2009;518:1460-1499.
20. Yuan WX, Chen SR, Chen H, Pan HL. Stimulation of alpha(1)-adrenoceptors reduces glutamatergic synaptic input from primary afferents through GABA(A) receptors and T-type Ca(2+) channels. Neuroscience 2009;158:1616-1624.
21. Brühl AB, Kaffenberger T, Herwig U. Serotonergic and noradrenergic modulation of emotion processing by single dose antidepressants. Neuropsychopharmacology 2010;35:521-533.
22. Gorea E, Adrien J. Serotonergic regulation of noradrenergic coerulean neurons: Electrophysiological evidence for the involvement of 5-HT2 receptors. Eur J Pharmacol 1988;154:285-291.
23. Gold PW, Chrousos GP. Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/EN. Mol Psychiatry 2002;7:254-275.
24. Stahl SM. Basic psychopharmacology of antidepressants, Part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59(Suppl 4):5-14.
25. Frazer A. Norepinephrine involvement in antidepressant action. J Clin Psychiatry 2000;61(Suppl 10):25-30.
26. Hood SD, Melichar JK, Taylor LG, et al. Noradrenergic function in generalized anxiety disorder: Impact of treatment with venlafaxine on the physiological and psychological responses to clonidine challenge. J Psychopharmacol 2010. doi:.
27. Young EA, Abelson JL, Cameron OG. Interaction of brain noradrenergic system and the hypothalamic-pituitary-adrenal (HPA) axis in man. Psychoneuroendocrinology 2005;30:807-814.
28. Brunello N, Blier P, Judd LL, et al. Noradrenaline in mood and anxiety disorders: Basic and clinical studies. Int Clin Psychopharmacol 2003;18:191-202.
29. Boudet C, Peyrin L. Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat. Arch Int Pharmacodyn Ther 1986;283:312-320.
30. Andersen J, Kristensen AS, Bang-Andersen B, Strømgaard K. Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and noradrenaline transporters. Chem Commun (Camb) 2009;25:3677-3692.
31. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004;36:723-746.
32. Uher R, Maier W, Hauser J, et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009;194:252-259.
33. Holtzheimer PE, Nemeroff CB. Emerging treatments for depression. Expert Opin Pharmacother 2006;7:2323-2339.
34. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, Frazer A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004;29:566-579.
35. Grunze H, Kasper S, Goodwin G, et al.; for the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression. World J Biol Psychiatry 2002;3:115-124.
36. Peet M, Peters S. Drug-induced mania. Drug Saf 1995;12:146-153.
37. Kimura M, Tateno A, Robinson RG. Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression: Merged analysis of nortriptyline trials. Am J Geriatr Psychiatry 2003;11:320-327.
38. Bandelow B, Zohar J, Hollander E, et al.; for the WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World J Biol Psychiatry 2002;3:171-199.
39. Bodmer M. Poisoning with antidepressants. Ther Umsch 2009;66:335-341.
40. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219.
41. Muller JE, Koen L, Seedat S, Stein DJ. Social anxiety disorder: Current treatment recommendations. CNS Drugs 2005;19:377-391.
42. Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev 2003;9:327-342.
43. Baldwin DS, Carabal E. Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression. Drugs Today (Barc) 1999;35:719-724.
44. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000;39:413-427.
45. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet 2009;373:746-758.
46. Cohen-Yavin I, Yoran-Hegesh R, Strous RD, Kotler M, Weizman A, Spivak B. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: An open-label, 8-week, methylphenidate-controlled trial. Clin Neuropharmacol 2009;32:179-182.
47. Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005;46:379-384.
48. Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis. J Psychiatr Res 2009;43:792-797.
49. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61(Suppl 1):26-32.
50. Seguí J, López-Muñoz F, Alamo C, Camarasa X, García-García P, Pardo A. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: A 12-week prospective study. J Psychopharmacol 2009;24:1201-1207.
51. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis. Depress Anxiety 1997;6:10-18.
52. Barton J. Atomoxetine: A new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child 2005;90(Suppl 1):i26-i29.
53. Prince JB. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: Update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 2006;15:13-50.
54. Ludolph AG, Udvardi PT, Schaz U, et al. Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol 2010;160:283-291.
55. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005;44:571-590.
56. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007;17:407-420.
57. Blier F. Psychopharmacology for the clinician. Treating depression with selective norepinephrine reuptake inhibitors. J Psychiatry Neurosci 2006;31:288.
58. Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs 2009;23:739-753.
59. Safeekh AT, Pinto D. Venlafaxine-induced psychotic symptoms. Indian J Psychiatry 2009;51:308-309.
60. Dell'Osso B, Buoli M, Baldwin DS, Altamura AC. Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: A comprehensive review of their clinical efficacy. Hum Psychopharmacol 2010;25:17-29.
61. Katzman M. Venlafaxine in the treatment of anxiety disorders. Expert Rev Neurother 2004;4:371-381
62. Wellington K, Perry CM. Venlafaxine extended-release: A review of its use in the management of major depression. CNS Drugs 2001;15:643-669.
63. Perry R, Cassagnol M. Desvenlafaxine: A new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther 2009;31(Pt 1):1374-1404.
64. Sopko MA, Jr., Ehret MJ, Grgas M. Desvenlafaxine: Another "me too" drug? Hum Psychopharmacol 2010;25:17-29.
65. Seo HJ, Sohi MS, Patkar AA, Masand PS, Pae CU. Desvenlafaxine succinate: A newer antidepressant for the treatment of depression and somatic symptoms. Postgrad Med 2010;122:125-138.
66. Kamath J, Handratta V. Desvenlafaxine succinate for major depressive disorder: A critical review of the evidence. Expert Rev Neurother 2008;8:1787-1797.
67. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 2009;31(Pt 1):1405-1423.
68. Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: A new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27:1126-1143.
69. Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf 2005;4:987-993.
70. Bandelow B, Zohar J, Hollander E, et al.; for the WFSBP Task Force on Treatment Guidelines for Anxiety Obsessive-Compulsive Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders: First Revision. World J Biol Psychiatry 2008;9:248-312.
71. Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: Findings from 42 placebo-controlled studies. Drug Saf 2007;30:437-455.
72. Pae CU, Tharwani H, Marks DM, Masand PS, Patkar AA. Atypical depression: A comprehensive review. CNS Drugs 2009;23:1023-1037.
73. Chang TT, Lêng CH, Wu JY, Lee SY, Wang YS, Chen YC, Lu RB. Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan. Chin J Physiol 2008;51:387-393.
74. Katz NS, Guiard BP, El Mansari M, Blier P. Effects of acute and sustained administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of monoaminergic neurons. J Psychopharmacol 2010;24:1223-1235.
75. Roz N, Rehavi M. Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci 2003;73:461-470.
76. Izenwasser S, Terry P, Heller B, Witkin JM, Katz JL. Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors. Eur J Pharmacol 1994;263:277-283.
77. Richelson E, Pharmacology of antidepressants: Characteristics of the ideal drug. Mayo Clin Proc 1994;69:1069-1081.
78. Petrie EC, Veith RC, Szot P. Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:845-856.
79. Ascher JA, Cole JO, Colin JN, et al. Bupropion: A review of its mechanism of antidepressant activity. J Clin Psychiatry 1995;56:395-401.
80. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999;288:88-92.
81. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 2006;12:178-207.
82. Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010;24:1209-1216.
83. Henningfield JE, Shiffman S, Ferguson SG, Gritz ER. Tobacco dependence and withdrawal: Science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 2009;123:1-16.
84. Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: A double-blind, placebo-controlled and randomized study. J Psychopharmacol 2010. doi:.
85. Spencer TJ, Biederman J, Wilens TE, Faraone SV. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002;63(Suppl 12):16-22.
86. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: From bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry 2005;7:106-113.
87. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005;66:974-981.
88. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE, Modell JG. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006;67:736-746.
89. Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006;26:482-488.
90. Zisook S, Rush AJ, Haight BR, Clines DC, Rockett CB. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006;59:203-210.
91. Starr P, Klein-Schwartz W, Spiller H, Kern P, Ekleberry SE, Kunkel S. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med 2009;27:911-915.
92. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005;66:253-259.
93. Chauhan B, Rani S, Guttikar S, Zope A, Jadon N, Padh H. Analytical method development and validation of mianserin hydrochloride and its metabolite in human plasma by LC-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2005;823:69-74.
94. Altamura AC, Melorio T. Mianserin metabolites. Br J Clin Pharmacol 1983;16:201-203.
95. Altamura AC, Mauri MC, Colacurcio F, et al. Trazodone in late life depressive states: A double-blind multicenter study versus amitriptyline and mianserin. Psychopharmacology (Berl) 1988;95(Suppl):S34-S36.
96. Wakeling A. Efficacy and side effects of mianserin, a tetracyclic antidepressant. Postgrad Med J 1983;59:229-231.
97. Demling J. Mianserin: Pharmacology and clinical aspects of an effective antidepressive agents. Fortschr Med 1993;111:497-500.
98. Kent JM. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression. Lancet 2000;355:911-918.
99. Bauer M, Whybrow PC, Angst J, et al.; for the WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder. World J Biol Psychiatry 2002;3:5-43.
100. Koenig AM, Thase ME. First-line pharmacotherapies for depression: What is the best choice? Pol Arch Med Wewn 2009;119:478-486.
101. Croom KF, Perry CM, Plosker GL. Mirtazapine: A review of its use in major depression and other psychiatric disorders. CNS Drugs 2009;23:427-452.
102. Liang Y, Shaw AM, Boules M, et al. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S, 2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS). J Pharmacol Exp Ther 2008;327:573-583.
103. Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: The next generation of antidepressants. Curr Neuropharmacol 2008;6:338-343.
104. Grunze HC. Quetiapine is effective in the treatment of adults in the acute phase of bipolar depression. Evid Based Ment Health 2010;13:88.
105. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010;121:106-115.
106. Pae CU, Sohi MS, Seo HJ, Patkar AA, Steffens DC, Masand PS. Quetiapine XR: Current status for the treatment of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1165-1173.
107. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008;18:81-98.
108. Bauer M, Tharmanathan P, Volz HP, Moeller HJ, Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: A meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009;259:172-185.
109. Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994;8:238-249.
110. Brunello N, Mendlewicz J, Kasper S, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002;12:461-475.
111. Papakostas GI, Montgomery SA, Thase ME, Katz JR, Krishen A, Tucker VL. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: A pooled survival analysis of 7 double-blind, randomized clinical trials. J Clin Psychiatry 2007;68:1907-1912.
112. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: A meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008;63:699-704.
113. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol 2008;22:843-848.
114. Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 2009;14:326-333.
115. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin 2009;25:161-175.